foxo4-dri senolytic peptide foxo4-dri FOX04-DRI 10mg FOXO4-DRI: The Senolytic Peptide That

Over time, sleep deprivation builds up, and can severely impact your emotional regulation

53 Despite the favorable results, no other clinical trials have been performed to date

Based on the phase 2 and phase 3 trial protocols: Weeks 1-4: 1 mg once weekly Weeks 5-8: 2 mg once weekly Weeks 9-12: 4 mg once weekly Weeks 13-16: 8 mg once weekly Weeks 17 onward: 12 mg once weekly (maximum dose) The starting dose of retatrutide is deliberately low because the triple-agonist mechanism produces more intense initial side effects than single-pathway compounds

All participants had detailed otorhinolaryngological examinations (the medical practice involving the ear, nose, and throat) and laboratory tests